Trial Profile
A Randomized, Open-Label, Multicenter Study of Alimta (Pemetrexed) Plus VELCADE (Bortezomib) or Alimta Alone or VELCADE Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Antineoplastic Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms POINT-II
- Sponsors Janssen-Cilag; Millennium
- 15 Dec 2006 New trial record.